Quantcast

Posts related to ‘Biotech’

High-Premium Biotech M&A Continues (AMGN, CELG, MITI, IBB)

Posted: January 26, 2012 at 5:08 pm

Thursday brought yet more merger and acquisition news in the ongoing buyout trends in the biotech sector.  Amgen Inc. (NASDAQ: AMGN) announced that it is going to acquire Micromet, Inc. (NASDAQ: ...
Read Full Story »

The $1,000 Genome Finally Arrives (LIFE)

Posted: January 10, 2012 at 11:47 am

Personalized medicine is coming... if you can afford it.  The quest for the $1,000 genomic map has been a race and it appears to be closer and closer.  News is out ...
Read Full Story »

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

Posted: January 4, 2012 at 8:01 am

For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like ...
Read Full Story »

Top Biotech Stock Picks For 2012 (ARIA, DNDN, GILD, HGSI, ILMN, INCY, JAZZ, LIFE, THRX, IBB, XBI)

Posted: December 28, 2011 at 7:01 am

The biotech sector has seen its share of ups and downs in 2011 and prior years.  It is almost always the case that some of the top performing stocks each ...
Read Full Story »

Small Caps With Over 50% Stock Upside in 2012 (PNK, CDXS, VVUS, SCMR)

Posted: December 22, 2011 at 11:18 am

Over the last week we have been reviewing some of the "Small Cap Stocking Stuffers" that features the top small cap ideas for 2012 from Credit Suisse.  After reviewing the ...
Read Full Story »

ARIAD Secures Much-Needed Capital for Trials, Commercialization, and Growth (ARIA)

Posted: December 15, 2011 at 9:54 am

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is raising cash to help support the commercialization of ponatinib in patients with resistant or intolerant CML and additional clinical development of its investigational targeted ...
Read Full Story »

The ‘Double’ Call in Human Genome (HGSI)

Posted: December 12, 2011 at 9:04 am

Human Genome Sciences Inc. (NASDAQ: HGSI) is not getting much of a boost despite being called as stock which could manage to double in price over the next 18 months ...
Read Full Story »

Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)

Posted: December 6, 2011 at 12:45 pm

Dendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment.  Unfortunately, PROVENGE sales ran slower than expected after the FDA took forever to ...
Read Full Story »

Winners as Pfizer Loses Lipitor Patent (PFE, TEVA, MYL, WPI)

Posted: November 29, 2011 at 11:28 am

Pfizer Inc. (NYSE: PFE) has a big day ahead of it.  While it has been known for years, it is a massive date: Lipitor goes off-patent and will have generic ...
Read Full Story »

Sequenom Files To Raise Capital (SQNM)

Posted: November 23, 2011 at 9:09 am

Sequenom, Inc. (NASDAQ: SQNM) has just filed to raise up to $150 million in a mixed securities shelf offering.  The diagnostics company could sell any combination of Common Stock, Preferred ...
Read Full Story »

Another Bump Up for Dendreon and PROVENGE (DNDN)

Posted: November 21, 2011 at 8:38 am

Dendreon Corporation (NASDAQ: DNDN) is surging on news that the Centers for Medicare and Medicaid Services will now cover the infusion costs associated with the administration of PROVENGE.  Dendreon noted ...
Read Full Story »

Gilead Paying Up (too much) for Pharmasset (GILD, VRUS)

Posted: November 21, 2011 at 7:51 am

Gilead Sciences Inc. (NASDAQ: GILD) is trading lower on news that it is spending some $11 billion to buy Pharmasset, Inc. (NASDAQ: VRUS).   What is interesting is that Pharmasset was ...
Read Full Story »

Vertex RA Study: When Good Is Not Good Enough (VRTX)

Posted: November 7, 2011 at 10:04 am

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) might have sounded as though shares would be up Monday morning if you were just looking at news over the weekend.  Instead, shares are down ...
Read Full Story »

Medivation, A Pain in the Rear for Dendreon (MDVN, DNDN)

Posted: November 3, 2011 at 10:59 am

Medivation, Inc. (NASDAQ: MDVN) is today's darling in biotech and emerging pharmaceuticals.  It and partner Astellas in Japan showed very positive data on its prostate cancer drug candidate. Its shares ...
Read Full Story »

Human Genome Sciences Back to Drinking from the Capital Well (HGSI)

Posted: November 2, 2011 at 7:39 am

Human Genome Sciences Inc. (NASDAQ: HGSI) is raising capital.  The company announced the sale of $400 million in Convertible Senior Notes which will mature in 2018. These notes are convertible into ...
Read Full Story »